Net Income

An international team, backed by a $2M grant from a global consortium and Microsoft, will use AI to personalize care for a long-overlooked disease.

A new blood test can predict when Alzheimer's symptoms will start, years in advance. This breakthrough could revolutionize research, but raises deep ethical questions.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

Dutch firm Besi reports booming orders for its advanced packaging tech, positioning it as a key enabler of the global AI infrastructure build-out.

Following the merger of Permascand and Magneto, the newly formed Elicron aims to dominate the green tech market with its advanced electrochemical solutions.

Early data reveals a novel immunotherapy, STC-1010, may activate the immune system against a common, treatment-resistant form of colorectal cancer.

As argenx prepares its full-year 2025 update, investors are watching if the VYVGART sales boom can fund a pipeline aimed at dominating autoimmune care.

A new report reveals a shocking spike in evasive malware, with 96% hidden in encrypted traffic, forcing a radical security rethink for businesses.

A class action lawsuit reveals a massive pump-and-dump scheme targeting China Liberal Education, raising questions of corporate complicity and investor recourse.

With its CEO and CFO set for key conferences, Aptar will address investors following a strong sales quarter but facing questions on profitability.

The precision tech firm posted record Q1 sales of $669M and a 15% jump in adjusted EPS, driven by a 21% surge in its semiconductor-focused segment.

Southern California Edison enhances its compensation program for Eaton Fire victims, offering more for legal fees and housing amid ongoing lawsuits.

As Cherry Hill Mortgage preps its 2025 results, investors eye dividends and strategy amid high interest rates and a challenging housing market.

The insurtech firm posted massive revenue growth driven by its AI platform, but one-time IPO costs obscure the full strength of its 2025 performance.

The nation's largest single-family landlord posts strong profits but faces slowing rent growth, shifting its strategy from buying homes to building them.

The AI analytics firm posted strong 2025 results, unveiled new AI agents, and boosted its buyback program, signaling confidence in its enterprise strategy.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

The Dubai-based SPAC is separating its shares and warrants. Here's what this key move means for investors and the company's search for a merger target.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

TPL shatters 2025 financial records despite price headwinds, fueled by strategic acquisitions and a major $50 million investment in data infrastructure.